{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"EW","limit":50},"count":50,"signals":[{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":18,"context":"d in the attached Proxy Statement to serve until our next annual meeting of stockholders and until their respective successors are duly elected and qualified  2.Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement  3.Ratification of the appointment of PricewaterhouseCoopersLLP as our independent registered public accounting firm for the fiscal year ending","filed_date":"2026-03-26","accession":"0001099800-26-000015","full_text":"https://origin.rootz.global/static/filing/0001099800-26-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":74,"context":"d uncertainty over third-party reimbursement. Failure in any of these areas could have a material effect on our prospects. Unsuccessful clinical trials or procedures relating to products could have a material adverse effect on our prospects.  The regulatory approval process for new products and new indications for existing products requires extensive clinical trials and procedures, including early clinical feasibility a","filed_date":"2026-02-25","accession":"0001099800-26-000009","full_text":"https://origin.rootz.global/static/filing/0001099800-26-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":49,"context":"ial, a randomized pivotal trial designed to study the groundbreaking EVOQUE system which demonstrated superiority compared to medical therapy alone for the one-year primary endpoint; we completed enrollment in the CLASP II TR trial for the PASCAL tricuspid implant; we completed enrollment in PROGRESS, a pivotal trial studying the treatment of moderate AS patients;  we sold our Critical Care product g","filed_date":"2025-03-26","accession":"0001099800-25-000013","full_text":"https://origin.rootz.global/static/filing/0001099800-25-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":30,"context":"d in the attached Proxy Statement to serve until our next annual meeting of stockholders and until their respective successors are duly elected and qualified  2.Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement  3.Ratification of the appointment of PricewaterhouseCoopersLLP as our independent registered public accounting firm for the fiscal year ending","filed_date":"2025-03-26","accession":"0001099800-25-000013","full_text":"https://origin.rootz.global/static/filing/0001099800-25-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":64,"context":"d uncertainty over third-party reimbursement. Failure in any of these areas could have a material effect on our prospects. Unsuccessful clinical trials or procedures relating to products could have a material adverse effect on our prospects.  The regulatory approval process for new products and new indications for existing products requires extensive clinical trials and procedures, including early clinical feasibility a","filed_date":"2025-02-28","accession":"0001099800-25-000005","full_text":"https://origin.rootz.global/static/filing/0001099800-25-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":9,"context":".0million and agreed to pay up to an additional $10.0million of milestone-based consideration for an option to acquire the medical technology company. As of December31, 2024 and 2023, the Company had invested $20.0million and $5.0million, respectively, in the medical technology company's preferred equity securities (included in Long-term Investments). In addition, the Company agreed to loan the medical technology comp","filed_date":"2025-02-28","accession":"0001099800-25-000005","full_text":"https://origin.rootz.global/static/filing/0001099800-25-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"e received approval in Japan for PASCAL Precision to treat patients with degenerative mitral regurgitation; we received CE Mark approval for our MITRIS RESILIA surgical mitral valve; we completed enrollment in the ENCIRCLE Trial, the first pivotal trial for our transfemoral mitral replacement therapy, SAPIEN M3; we received FDA approval for a SAPIEN M3 continued access program; we restarted enrollmen","filed_date":"2024-03-26","accession":"0001099800-24-000032","full_text":"https://origin.rootz.global/static/filing/0001099800-24-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":29,"context":"d in the attached Proxy Statement to serve until our next annual meeting of stockholders and until their respective successors are duly elected and qualified  2.Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement  3.Ratification of the appointment of PricewaterhouseCoopersLLP as our independent registered public accounting firm for the fiscal year ending","filed_date":"2024-03-26","accession":"0001099800-24-000032","full_text":"https://origin.rootz.global/static/filing/0001099800-24-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"we received approval in Japan for PASCAL Precision to treat patients with degenerative mitral regurgitation;we received CE Mark approval for our MITRIS RESILIA surgical mitral valve;we completed enrollment in the ENCIRCLE Trial, the first pivotal trial for our transfemoral mitral replacement therapy, SAPIEN M3;we received FDA approval for a SAPIEN M3 continued access program;we restarted enrollment","filed_date":"2024-02-12","accession":"0001099800-24-000004","full_text":"https://origin.rootz.global/static/filing/0001099800-24-000004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":59,"context":"d uncertainty over third-party reimbursement. Failure in any of these areas could have a material effect on our prospects. Unsuccessful clinical trials or procedures relating to products could have a material adverse effect on our prospects.  The regulatory approval process for new products and new indications for existing products requires extensive clinical trials and procedures, including early clinical feasibility a","filed_date":"2024-02-12","accession":"0001099800-24-000004","full_text":"https://origin.rootz.global/static/filing/0001099800-24-000004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":13,"context":"$45.0million secured promissory note agreement with a privately-held medical device company (the \"Investee\"), of which $30.0million had been advanced as of December31, 2023. Also in 2021, the Company invested $39.3million, included in \"Long-term Investments,\" in the Investee's preferred equity securities and paid $13.1million, included in \"Other Assets,\" for an option to acquire the Investee. Pursuant to the agreement","filed_date":"2024-02-12","accession":"0001099800-24-000004","full_text":"https://origin.rootz.global/static/filing/0001099800-24-000004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":24,"context":"d in the attached Proxy Statement to serve until our next annual meeting of stockholders and until their respective successors are duly elected and qualified  2.Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement  3.Approval, on an advisory basis, of the frequency of future advisory votes on the compensation of our named executive officers 4.Ratification","filed_date":"2023-03-28","accession":"0001099800-23-000013","full_text":"https://origin.rootz.global/static/filing/0001099800-23-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":26,"context":"d uncertainty over third-party reimbursement. Failure in any of these areas could have a material effect on our prospects. Unsuccessful clinical trials or procedures relating to products could have a material adverse effect on our prospects.  The regulatory approval process for new products and new indications for existing products requires extensive clinical trials and procedures, including early clinical feasibility a","filed_date":"2023-02-13","accession":"0001099800-23-000005","full_text":"https://origin.rootz.global/static/filing/0001099800-23-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"patients:  |  |  |  Invested in increasing disease and therapy awareness, pursued further therapy expansion, and advanced new technologies in transcatheter aortic valve replacement. We completed enrollment in EARLY TAVR, a pioneering pivotal trial studying the treatment of severe aortic stenosis (AS) patients before their symptoms develop. Separately, we initiated enrollment in our PROGRESS pivotal","filed_date":"2022-03-22","accession":"0001193125-22-081590","full_text":"https://origin.rootz.global/static/filing/0001193125-22-081590.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":22,"context":"ched Proxy Statement to serve until our next annual meeting of stockholders and until their respective successors are duly elected and qualified | | |  |  2. |  Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement | | |  |  3. |  Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fisca","filed_date":"2022-03-22","accession":"0001193125-22-081590","full_text":"https://origin.rootz.global/static/filing/0001193125-22-081590.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":23,"context":"d uncertainty over third-party reimbursement. Failure in any of these areas could have a material effect on our prospects. Unsuccessful clinical trials or procedures relating to products could have a material adverse effect on our prospects.  The regulatory approval process for new products and new indications for existing products requires extensive clinical trials and procedures, including early clinical feasibility a","filed_date":"2022-02-14","accession":"0001099800-22-000005","full_text":"https://origin.rootz.global/static/filing/0001099800-22-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":40,"context":"tricuspid valve disease |  |  |  |  17 |  |  |  Achieved milestones around new approvals of mitral and tricuspid therapies in a market outside of the United States  Missed on some clinical trial enrollment goals due to the impact of COVID on the health care system  Achieved milestones around clinical advancements in tricuspid replacement therapies | | |  |  |  | | |  Strengthen global leadership in","filed_date":"2021-03-23","accession":"0001193125-21-091192","full_text":"https://origin.rootz.global/static/filing/0001193125-21-091192.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":17,"context":"ched Proxy Statement to serve until our next annual meeting of stockholders and until their respective successors are duly elected and qualified | | |  |  2. |  Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement | | |  |  3. |  Approval of the Amendment and Restatement of the Companys 2001 Employee Stock Purchase Plan for United States Employees (the U.S","filed_date":"2021-03-23","accession":"0001193125-21-091192","full_text":"https://origin.rootz.global/static/filing/0001193125-21-091192.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"VR and Surgical products dropped significantly. Beginning in the second quarter of 2020, procedure volumes improved. In the second quarter of 2020, we also started to progressively resume patient enrollment in all clinical trials that were voluntarily paused or slowed at the end of the first quarter of 2020. While we saw improvements to pre-COVID levels when we resumed enrollment, procedure volumes a","filed_date":"2021-02-12","accession":"0001099800-21-000007","full_text":"https://origin.rootz.global/static/filing/0001099800-21-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":20,"context":"d uncertainty over third-party reimbursement. Failure in any of these areas could have a material effect on our prospects. Unsuccessful clinical trials or procedures relating to products could have a material adverse effect on our prospects.  The regulatory approval process for new products and new indications for existing products requires extensive clinical trials and procedures, including early clinical feasibility a","filed_date":"2021-02-12","accession":"0001099800-21-000007","full_text":"https://origin.rootz.global/static/filing/0001099800-21-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":18,"context":", diversity and deep industry expertise necessary to continue to effectively oversee Edwards differentiated strategy. As a result of our robust evaluation and refreshment process, since 2014, we have appointed five new directors to the Board. In addition, Ramona Sequeira, a new director nominee, will be standing for election at this years Annual Meeting for the first time. Our directors greatly value the perspectives of our","filed_date":"2020-03-25","accession":"0001193125-20-085079","full_text":"https://origin.rootz.global/static/filing/0001193125-20-085079.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":30,"context":"nificant effort or investment in circumstances where the items supplied are integral to product performance or incorporate unique technology, and the loss of any existing supply contract could have a material adverse effect on us. Regulatory agencies in the United States or other international geographies from time to time have limited or banned the use of certain materials used in the manufacture of our products. In th","filed_date":"2020-02-14","accession":"0001099800-20-000005","full_text":"https://origin.rootz.global/static/filing/0001099800-20-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":17,"context":"y Statement to serve until our next annual meeting of stockholders and until their respective successors are duly elected and qualified | | |  |  Proposal 2. |  Approval, on an advisory basis, of the named executive officer compensation disclosed in the attached Proxy Statement | | |  |  Proposal 3. |  Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for","filed_date":"2019-03-27","accession":"0001193125-19-088534","full_text":"https://origin.rootz.global/static/filing/0001193125-19-088534.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":29,"context":"nificant effort or investment in circumstances where the items supplied are integral to product performance or incorporate unique technology, and the loss of any existing supply contract could have a material adverse effect on us. Regulatory agencies in the United States or other international geographies from time to time have limited or banned the use of certain materials used in the manufacture of our products. In th","filed_date":"2019-02-15","accession":"0001099800-19-000004","full_text":"https://origin.rootz.global/static/filing/0001099800-19-000004.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":98,"match_count":11,"context":"illion. At both June30, 2024 and December31, 2023, the Company had advanced $30.0million under the promissory note (included in Other Assets). As of June30, 2024 and December31, 2023, the Company had invested $42.8million and $39.3million, respectively, in the Investee's preferred equity securities (included in Long-term Investments) and had paid $20.9million and $13.1million, respectively, for an option to acquire th","filed_date":"2024-07-31","accession":"0001099800-24-000078","full_text":"https://origin.rootz.global/static/filing/0001099800-24-000078.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"VR and Surgical products dropped significantly. Beginning in the second quarter of 2020, procedure volumes improved. In the second quarter of 2020, we also started to progressively resume patient enrollment in all clinical trials that were voluntarily paused or slowed at the end of the first quarter of 2020. While we saw improvements to pre-COVID levels when we resumed enrollment, procedure volumes a","filed_date":"2022-02-14","accession":"0001099800-22-000005","full_text":"https://origin.rootz.global/static/filing/0001099800-22-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":94,"match_count":8,"context":"s on Impairment within non-operating income on the consolidated statement of operations. During the year ended December31, 2025, the Company entered into a simple agreement for future equity where it invested $10.0million in the medical device companys stock (included in Long-term Investments).In April 2021, the Company entered into a secured promissory note agreement, a preferred stock purchase agreement, and an opti","filed_date":"2026-02-25","accession":"0001099800-26-000009","full_text":"https://origin.rootz.global/static/filing/0001099800-26-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":90,"match_count":10,"context":"siders our Companys compensation policies and practices to determine if their structure or implementation provides incentives to employees to take unnecessary or inappropriate risks that could have a material adverse effect on our Company. Our Compensation and Governance Committee also reviews compensation and benefits plans affecting employees, in addition to those applicable to executive officers. Our Compensation and","filed_date":"2026-03-26","accession":"0001099800-26-000015","full_text":"https://origin.rootz.global/static/filing/0001099800-26-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":90,"match_count":10,"context":"ncome on the consolidated condensed statement of operations. During the three months ended September30, 2025, the 15Table of ContentsCompany entered into a simple agreement for future equity where it invested $10.0million in the medical device companys stock (included in Other Assets).In April 2021, the Company entered into a promissory note agreement, a preferred stock purchase agreement, and an option agreement with","filed_date":"2025-11-05","accession":"0001099800-25-000062","full_text":"https://origin.rootz.global/static/filing/0001099800-25-000062.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"ical valves treated with our proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves; we completed enrollment in the CLASP IIF trial for the PASCAL transcatheter valve repair system; we announced ENCIRCLE pivotal trial results demonstrating successful patient outcomes supporting our portfolio of mitral an","filed_date":"2026-03-26","accession":"0001099800-26-000015","full_text":"https://origin.rootz.global/static/filing/0001099800-26-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":88,"match_count":6,"context":"es of each particular case or claim, the jurisdiction in which each suit is brought, and differences in applicable law. Management does not believe that any loss relating to the Lawsuits would have a material adverse effect on the Company's overall financial condition, results of operations or cash flows. However, the resolution of one or more of the Lawsuits in any reporting period could have a material adverse impact","filed_date":"2026-08-04","accession":"0001099800-26-000043","full_text":"https://origin.rootz.global/static/filing/0001099800-26-000043.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":82,"match_count":9,"context":"siders our Companys compensation policies and practices to determine if their structure or implementation provides incentives to employees to take unnecessary or inappropriate risks that could have a material adverse effect on our Company. Our Compensation and Governance Committee also reviews compensation and benefits plans affecting employees, in addition to those applicable to executive officers. Our Compensation and","filed_date":"2023-03-28","accession":"0001099800-23-000013","full_text":"https://origin.rootz.global/static/filing/0001099800-23-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"ISCEND II trial, a randomized pivotal trial designed to study the EVOQUE system and which demonstrated superiority compared to medical therapy alone for the one-year primary endpoint;we completed enrollment in the CLASP II TR trial for the PASCAL tricuspid implant;we completed enrollment in PROGRESS, a pivotal trial studying the treatment of moderate AS patients;we sold our Critical Care product grou","filed_date":"2025-02-28","accession":"0001099800-25-000005","full_text":"https://origin.rootz.global/static/filing/0001099800-25-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"ments for patients:  Invested in increasing disease and therapy awareness, pursued further therapy expansion, and advanced new technologies in transcatheter aortic valve replacement. We completed enrollment in EARLY TAVR, a pioneering pivotal trial studying the treatment of severe aortic stenosis (AS) patients before their symptoms develop. Separately, we initiated enrollment in our PROGRESS pivotal","filed_date":"2023-03-28","accession":"0001099800-23-000013","full_text":"https://origin.rootz.global/static/filing/0001099800-23-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":77,"match_count":9,"context":"aws of its jurisdiction of incorporation and has all requisite corporate or other organizational authority to conduct its business in each jurisdiction in which the failure so to qualify would have a material adverse effect on the business, properties, assets, operations or condition (financial or otherwise) of the Company and its Subsidiaries, taken as a whole.  62  SECTION 3.02 Authorization; No Violation. The Transac","filed_date":"2022-07-21","accession":"0001193125-22-199173","full_text":"https://origin.rootz.global/static/filing/0001193125-22-199173.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":74,"match_count":8,"context":"siders our Companys compensation policies and practices to determine if their structure or implementation provides incentives to employees to take unnecessary or inappropriate risks that could have a material adverse effect on our Company. Our Compensation and Governance Committee also reviews compensation and benefits plans affecting employees, in addition to those applicable to executive officers. Our Compensation and","filed_date":"2025-03-26","accession":"0001099800-25-000013","full_text":"https://origin.rootz.global/static/filing/0001099800-25-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":74,"match_count":8,"context":"siders our Companys compensation policies and practices to determine if their structure or implementation provides incentives to employees to take unnecessary or inappropriate risks that could have a material adverse effect on our Company. Our Compensation and Governance Committee also reviews compensation and benefits plans affecting employees, in addition to those applicable to executive officers. Our Compensation and","filed_date":"2024-03-26","accession":"0001099800-24-000032","full_text":"https://origin.rootz.global/static/filing/0001099800-24-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":66,"match_count":7,"context":"siders the Companys compensation policies and practices to determine if their structure or implementation provides incentives to employees to take unnecessary or inappropriate risks that could have a material adverse effect on the Company. The Compensation and Governance Committee also reviews compensation and benefits plans affecting employees, in addition to those applicable to executive officers. The Compensation and","filed_date":"2022-03-22","accession":"0001193125-22-081590","full_text":"https://origin.rootz.global/static/filing/0001193125-22-081590.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":62,"match_count":4,"context":"es of each particular case or claim, the jurisdiction in which each suit is brought, and differences in applicable law. Management does not believe that any loss relating to the Lawsuits would have a material adverse effect on the Company's overall financial condition, results of operations or cash flows. However, the resolution of one or more of the Lawsuits in any reporting period could have a material adverse impact","filed_date":"2026-05-06","accession":"0001099800-26-000026","full_text":"https://origin.rootz.global/static/filing/0001099800-26-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":58,"match_count":6,"context":"both September30, 2024 and December31, 2023, the Company had advanced $30.0million under the promissory note (included in Other Assets). As of September30, 2024 and December31, 2023, the Company had invested $42.8million and $39.3million, respectively, in the Investee's preferred equity securities (included in Long-term Investments) and had paid $20.9million and $13.1million, respectively, for an option to acquire th","filed_date":"2024-11-06","accession":"0001099800-24-000086","full_text":"https://origin.rootz.global/static/filing/0001099800-24-000086.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":58,"match_count":6,"context":"lion. At both March31, 2024 and December31, 2023, the Company had advanced $30.0million under the promissory note (included in Other Assets). As of March31, 2024 and December31, 2023, the Company had invested $42.8million and $39.3million, respectively, in the Investee's preferred equity securities (included in Long-term Investments) and had paid $20.9million and $13.1million, respectively, for an option to acquire th","filed_date":"2024-04-29","accession":"0001099800-24-000039","full_text":"https://origin.rootz.global/static/filing/0001099800-24-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":56,"match_count":7,"context":"ties, netThe change in fair value of contingent consideration liabilities resulted in gains of $26.2 million during 2023, primarily due to changes in projected probabilities of milestone achievement. Restructuring Charges, Separation Costs, and OtherIn September 2024, we recorded an expense of $32.9million primarily related to severance expenses associated with a global workforce realignment impacting approximately 36","filed_date":"2025-02-28","accession":"0001099800-25-000005","full_text":"https://origin.rootz.global/static/filing/0001099800-25-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":56,"match_count":7,"context":"tements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include risk and uncertainties associated with the spin-off of our Critical Care product group our ability to develop new products and  4 avoid manufacturing and quality issues challenges related to clinical trial or commercial results or new product approvals a","filed_date":"2024-02-06","accession":"0001099800-24-000002","full_text":"https://origin.rootz.global/static/filing/0001099800-24-000002.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"ceived CE Mark in February 2019. In mitral repair, we continue to enroll our CLASP IID U.S. pivotal trial to study PASCAL in primary, or degenerative, mitral valve disease. We also have initiated enrollment in our CLASP IIF pivotal trial for patients with secondary, or functional, mitral valve disease. In September 2019, we received FDA approval for our CLASP IITR pivotal trial to study PASCAL in pat","filed_date":"2020-02-14","accession":"0001099800-20-000005","full_text":"https://origin.rootz.global/static/filing/0001099800-20-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"ogram. Consistent with vesting standards established by the Company for its stock option grants to executives who are retirement-eligible, options vest and become exercisable in 36 equal monthly installments beginning one month after the award date, and are subject to the executives continued employment with the Company. The material terms of the options are described in the section Equity Incentive","filed_date":"2019-03-27","accession":"0001193125-19-088534","full_text":"https://origin.rootz.global/static/filing/0001193125-19-088534.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":53,"match_count":6,"context":"both June30, 2025 and December31, 2024, the Company had advanced a total of $45.0million under the promissory note (included in Other Assets). As of June30, 2025 and December31, 2024, the Company had invested $44.6million and $42.8 million, respectively, in the Investee's preferred equity securities (included in Long-term Investments) and had paid $24.9million and $20.9million, respectively, for an option to acquire t","filed_date":"2025-08-06","accession":"0001099800-25-000048","full_text":"https://origin.rootz.global/static/filing/0001099800-25-000048.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":50,"match_count":5,"context":"siders the Companys compensation policies and practices to determine if their structure or implementation provides incentives to employees to take unnecessary or inappropriate risks that could have a material adverse effect on the Company. The Compensation Committee also reviews compensation and benefits plans affecting employees, in addition to those applicable to executive officers. The Compensation Committee has dete","filed_date":"2021-03-23","accession":"0001193125-21-091192","full_text":"https://origin.rootz.global/static/filing/0001193125-21-091192.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":50,"match_count":5,"context":"siders the Companys compensation policies and practices to determine if their structure or implementation provides incentives to employees to take unnecessary or inappropriate risks that could have a material adverse effect on the Company. The Compensation Committee also reviews compensation and benefits plans affecting employees, in addition to those applicable to executive officers. The Compensation Committee has dete","filed_date":"2020-03-25","accession":"0001193125-20-085079","full_text":"https://origin.rootz.global/static/filing/0001193125-20-085079.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":50,"match_count":5,"context":"siders the Companys compensation policies and practices to determine if their structure or implementation provides incentives to employees to take unnecessary or inappropriate risks that could have a material adverse effect on the Company. The Compensation Committee also reviews compensation and benefits plans affecting employees, in addition to those applicable to executive officers. The Compensation Committee has dete","filed_date":"2019-03-27","accession":"0001193125-19-088534","full_text":"https://origin.rootz.global/static/filing/0001193125-19-088534.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"EW","company":"Edwards Lifesciences Corp","exchange":"NYSE","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"restructuring","strength":48,"match_count":6,"context":"ies, netThe change in fair value of contingent consideration liabilities resulted in gains of $12.5 million during 2025, primarily due to changes in projected probabilities of milestone achievements. Restructuring Charges, Separation Costs, and OtherIn 2025 and 2024, we recorded expenses of $13.1million and $32.9million, respectively, related to severance associated with realignment initiatives. In 2025 and 2024, we a","filed_date":"2026-02-25","accession":"0001099800-26-000009","full_text":"https://origin.rootz.global/static/filing/0001099800-26-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"41c0622793c171e9e12c768fc26d6888431d7942a2e85f4d4ebd0442465f2e65","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"6545046ad387742aed49e803b5209b83ae33095823fee428c8145c0226dea116","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":167,"hourly_limit":500,"remaining":333,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}